Hsbc Holdings PLC Acquires Shares of 13,850 Arrowhead Pharmaceuticals, Inc. $ARWR

Hsbc Holdings PLC acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 13,850 shares of the biotechnology company’s stock, valued at approximately $173,000.

Several other institutional investors also recently bought and sold shares of the company. Oak Ridge Investments LLC increased its stake in Arrowhead Pharmaceuticals by 2.5% in the 1st quarter. Oak Ridge Investments LLC now owns 33,734 shares of the biotechnology company’s stock valued at $430,000 after buying an additional 823 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Arrowhead Pharmaceuticals by 9.0% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 14,476 shares of the biotechnology company’s stock valued at $184,000 after buying an additional 1,195 shares during the period. GAMMA Investing LLC boosted its position in shares of Arrowhead Pharmaceuticals by 297.6% during the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,628 shares in the last quarter. Captrust Financial Advisors boosted its position in shares of Arrowhead Pharmaceuticals by 13.5% during the 4th quarter. Captrust Financial Advisors now owns 17,074 shares of the biotechnology company’s stock worth $321,000 after purchasing an additional 2,035 shares in the last quarter. Finally, KBC Group NV boosted its position in shares of Arrowhead Pharmaceuticals by 40.8% during the 1st quarter. KBC Group NV now owns 7,356 shares of the biotechnology company’s stock worth $94,000 after purchasing an additional 2,132 shares in the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have commented on ARWR. Chardan Capital restated a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 11th. B. Riley upgraded shares of Arrowhead Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 11th. Wall Street Zen lowered shares of Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, July 18th. Royal Bank Of Canada decreased their target price on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an “outperform” rating on the stock in a research report on Friday, August 8th. Finally, HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Arrowhead Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $43.14.

Arrowhead Pharmaceuticals Price Performance

Arrowhead Pharmaceuticals stock opened at $29.08 on Friday. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $9.57 and a 52 week high of $29.34. The company has a quick ratio of 4.87, a current ratio of 4.87 and a debt-to-equity ratio of 0.39. The firm’s 50-day simple moving average is $18.78 and its 200 day simple moving average is $16.26. The firm has a market capitalization of $4.02 billion, a PE ratio of -22.72 and a beta of 1.00.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.32). The business had revenue of $27.77 million for the quarter, compared to the consensus estimate of $29.01 million. During the same quarter last year, the business posted ($1.38) EPS. On average, equities research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Insider Transactions at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 15,000 shares of the company’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $25.00, for a total value of $375,000.00. Following the transaction, the insider directly owned 247,122 shares in the company, valued at approximately $6,178,050. This represents a 5.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders have sold 25,000 shares of company stock valued at $575,000. 4.30% of the stock is currently owned by corporate insiders.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.